ILC Cell Technology
Cutting-edge stem cell technology for creating Islet-Like Cluster Cells.
Islet Like Cluster Cells
Regenerative Medical Solutions (RMS) has developed a novel and proprietary ILC cell technology to transform stem cells into insulin producing cells. Our pancreatic islet like cluster (ILC) cells are morphologically and functionally similar to β islet cells isolated from the human body. They contain glucagon producing alpha cells, somatostatin producing delta cells and insulin producing β islet cells.
RMS is utilizing and building upon patented technology developed at RMS and the University of Wisconsin- Madison under world renowned stem cell scientist and pancreatic transplant surgeon, Dr. Jon Odorico, and RMS’ dedicated team of scientists. Dr. Odorico has been working in the field of stem cells, diabetes and regenerative medicine for over 20 years. He has collaborated with Dr. James Thomson, the father of stem cell research. By using stem cells to create functional pancreatic islet-like cells.
ILC Cell Technology Applications
Regenerative Medical Solutions leverages our ILC cell technology to develop two key products for ILC Cell Therapeutics.
ILC Cell Generation
A specially formulated cryopreserved single cell ILC’s that can be used for diabetes research, drug discovery, and toxicity testing. These ILCs closely resemble human cadaveric islet’s morphologically, express similar key pancreatic markers (NKX6.1 and PDX1), and have functional insulin production. RMS ILCs can offer a reliable and scalable option for researchers and pharmaceutical developers to advance diabetes treatments and better understand cellular responses in pre-clinical trials.
ILC Cellular Therapeutic Candidate for Diabetes Treatment
RMS’s innovative diabetes cellular therapeutic, currently in pre-clinical development, leverages stem cell technology to create Islet-Like Clusters (ILCs) aimed at treating both Type 1 and Type 2 diabetes. By utilizing both autologous and allogeneic approaches, RMS is developing therapies where patient-derived or donor-derived iPSCs are differentiated into ILCs, which can be transplanted to restore insulin production and regulate blood glucose levels. This promising therapeutic candidate has the potential to offer a functional cure for diabetes, addressing the underlying cause of insulin deficiency, and is progressing towards clinical trials to assess its safety and efficacy.
Patented Breakthroughs in Stem Cell Technology and Diabetes Treatment
RMS has built a substantial IP and know-how (trade secret) portfolio over the years in additional to exclusive and non-exclusive licensing of IP from academic institutions.
- Issued Patent (8,685,730): “Methods and Devices For Differentiating Pluripotent Stem Cells Into Cells Of The Pancreatic Lineage”
- Issued Patent (9,540,613 B2), RMS was a co-inventor with University of Wisconsin: “Methods For Producing Insulin-secreting Beta Cells From Human Pluripotent Stem Cells”
- Issued Patent (9,828,634): Markers for differentiation of stem cells into differentiated cell populations.
- Issued Patent (9,765,302): Compositions and methods for differentiating stem cells into cell. populations comprising beta-like cells.
- Non-exclusive license from Academia Japan to practice iPSC methods for both research tools and therapy.
